Akèy › Kansè (tout kalite) › Massachusetts › Boston
Etid klinik pou Kansè (tout kalite) nan Boston, MA
86 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Dana-Farber Cancer Institute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center - Research, Boston
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Ap rekriteEtid obsèvasyon
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Boston
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ap rekriteFaz 3
- Investigative Site, Boston
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Dana Farber Cancer Center ( Site 4013), Boston
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Ap rekriteFaz 3
- Dana Farber/Harvard Cancer Center, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Ap rekrite
- Massachusetts General Hospital, Boston
Pan Tumor Rollover Study
Ap rekriteFaz 2
- Dana_Farber Cancer Institute (DFCI), Boston
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Ap rekriteFaz 3
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Ap rekriteFaz 3
- Dana-Farber Cancer Institute /ID# 279690, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Ap rekriteFaz 2/3
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute ( Site 3013), Boston
Statins to Prevent Cancer Associated Blood Clots
Ap rekriteFaz 4
- Beth Isreal Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
Ap rekrite
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
Ap rekrite
- Dana-Farber Cancer Institute, Boston
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Ap rekriteFaz 2
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Boston Medical Center, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- Dana Farber Cancer Institute, Boston
Lurbinectedin in FET-Fused Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Prostate Active Surveillance Study
Ap rekriteEtid obsèvasyon
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital (MG), Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
BRIDGE-SIC Efficacy Trial
Ap rekrite
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Boston Medical Center, Boston
- ak 1 plis
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Ap rekriteFaz 1Volontè an sante akeyi
- Boston Medical Center, Boston
- Massachusetts General Hospital (MGH), Charlestown · 1 mi lwen
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Ap rekriteFaz 1
- Brigham and Women's Hospital, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Ap rekriteFaz 2
- Massachusetts General Hospital /ID# 273608, Boston
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The STOP-MED CTRCD Trial
Ap rekriteFaz 4
- Brigham and Women's Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Ap rekriteFaz 1
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Childhood Cancer Survivor Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Dana-Farber Cancer Institute, Boston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Ap rekrite
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Boston
- Research Site, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Multisite Implementation of COMPRENDO
Ap rekriteVolontè an sante akeyi
- Dana Farber Cancer Institute/Boston Children's Hospital, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
- Massachusetts General Hospital,, Boston
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Ap rekriteFaz 1
- GSK Investigational Site, Boston
Video Inspired Discussions About Ethical Outcomes in Pediatrics
Ap rekrite
- Dana Farber Cancer Institute, Boston
On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
Ap rekriteMande peman pou patisipan yo
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Ap rekriteFaz 2
- Dana Farber Cancer Institute, Boston
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Ap rekriteFaz 2
- Massachusetts Eye and Ear, Boston
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
Ap rekrite
- Dana-Farber Cancer Institute, Boston
Positron Emission Tomography (PET) Imaging of Thrombosis
Ap rekriteFaz 1Volontè an sante akeyi
- Massachusetts General Hospital, Boston
Primary Tumor Research and Outcomes Network
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Ap rekrite
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
PediRISE Feasibility
Ap rekrite
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
Ap rekrite
- Massachusetts General Hospital Cancer Center, Boston
A Study of YL242 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1/2
- US-204, Boston
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Ap rekriteEtid obsèvasyon
- Boston Children's Hospital, Boston
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
Ap rekriteVolontè an sante akeyi
- Codman Square Health Center, Boston
- East Boston Neighborhood Health Center, East Boston · 2 mi lwen
Childhood Cancer Predisposition Study (CCPS)
Ap rekriteEtid obsèvasyon
- Dana Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Ap rekrite
- Massachusetts General Hospital Cancer Center, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Ap rekrite
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Ap rekriteFaz 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
Ap rekriteVolontè an sante akeyi
- Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY110 etid
- Los Angeles, CA73 etid
- Nashville, TN65 etid
- Philadelphia, PA59 etid
- Durham, NC58 etid
- Washington, DC58 etid
- Chicago, IL51 etid
- Seattle, WA49 etid
- Atlanta, GA49 etid
- Arlington, VA48 etid
- St. Louis, MO46 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
- Kansè pankreyas43 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.